Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial von Soria, Jean-Charles, Prof, Felip, Enriqueta, MD, Cobo, Manuel, MD, Lu, Shun, MD, Syrigos, Konstantinos, Prof, Lee, Ki Hyeong, MD, Göker, Erdem, MD, Georgoulias, Vassilis, Prof, Li, Wei, MD, Isla, Dolores, MD, Guclu, Salih Z, MD, Morabito, Alessandro, MD, Min, Young J, MD, Ardizzoni, Andrea, MD, Gadgeel, Shirish M, Prof, Wang, Bushi, PhD, Chand, Vikram K, MD, Goss, Glenwood D, Prof

Volltext

OA23.03 Second-Line Afatinib for Advanced Squamous Cell Carcinoma of the Lung: Analysis of Afatinib Long-Term Responders in the Phase III LUX-Lung 8 Trial von Goss, Glenwood, Cobo, Manuel, Lu, Shun, Syrigos, Kostas, Morabito, Alessandro, Albert, Istvan, Herodek, Gabriella, Chan, Samuel, Ostoros, Gyula, Sarosi, Veronika, Kiraly, Zsolt, Savior, Deric, Barton, Rachael, Medina, Francisco, Subramanian, Sundaram, Ardizzoni, Andrea, Felip, Enriqueta, Gadgeel, Shirish, Georgoulias, Vassilis, Love, James, Bühnemann, Claudia, Gibson, Neil, Ehrnrooth, Eva, Soria, Jean-Charles, Dupuis, Nicholas

Volltext

A Single Centre Experience with Phenotype Dependent Perioperative Chemotherapy for Primary Breast Cancer von Kullmann, Tamás, Agyemang-Prempeh, Kofi, Ambrus, Adél, Herodek, Gabriella, Hillier, Balázs, Kocsis, Károly, Laszip, Ilona, Mák, Mária, Pintér, Tamás, Sipőcz, István

Volltext

O36-3 Analysis of long-term response to second-line afatinib in patients with advanced SCC of the lung in the LUX-Lung 8 trial von James Chih-Hsin Yang, Glenwood Goss, Manuel Cobo, Shun Lu, Konstantinos Syrigos, Alessandro Morabito, Istvan Albert, Gabriella Herodek, Samuel Chan, Gyula Ostoros, Veronika Sarosi, Zsolt Kiraly, Deric Savior, Andrea Ardizzoni, Enriqueta Felip, Shirish M Gadgeel, Vassilis Georgoulias, Nicholas Dupuis, Eva Ehrnrooth, Jean-Charles Soria

Volltext